Diadema Partners LP Takes $1.38 Million Position in Replimune Group, Inc. (NASDAQ:REPL)

Diadema Partners LP bought a new stake in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 114,000 shares of the company's stock, valued at approximately $1,381,000. Diadema Partners LP owned about 0.17% of Replimune Group as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. State Street Corp grew its stake in shares of Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company's stock valued at $25,647,000 after buying an additional 1,182,181 shares during the last quarter. Barclays PLC grew its position in Replimune Group by 165.5% during the 3rd quarter. Barclays PLC now owns 158,491 shares of the company's stock worth $1,738,000 after acquiring an additional 98,791 shares during the last quarter. Geode Capital Management LLC increased its stake in Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company's stock worth $15,657,000 after purchasing an additional 217,308 shares during the period. JPMorgan Chase & Co. lifted its position in Replimune Group by 3.3% in the third quarter. JPMorgan Chase & Co. now owns 249,349 shares of the company's stock valued at $2,733,000 after purchasing an additional 8,074 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Replimune Group by 14.7% in the fourth quarter. SG Americas Securities LLC now owns 26,291 shares of the company's stock worth $318,000 after purchasing an additional 3,374 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company's stock.

Analysts Set New Price Targets

REPL has been the subject of several analyst reports. JPMorgan Chase & Co. increased their price target on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. BMO Capital Markets increased their target price on shares of Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. Finally, HC Wainwright boosted their price target on Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $19.43.

Replimune Group Stock Down 0.1 %

Shares of REPL stock traded down $0.01 during midday trading on Friday, reaching $9.05. 362,638 shares of the stock were exchanged, compared to its average volume of 867,680. The firm has a market cap of $696.99 million, a PE ratio of -2.95 and a beta of 1.26. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The company's 50 day moving average is $10.24 and its two-hundred day moving average is $11.66. Replimune Group, Inc. has a 1 year low of $4.92 and a 1 year high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). On average, equities research analysts predict that Replimune Group, Inc. will post -2.97 EPS for the current year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.